Hos patienter, der fik en ACE- hæmmer uden betablokker, var mortaliteten uanset årsag ensartet (p=NS) i valsartan - (21, 8%) og placebo - (22, 5%) gruppen.
In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups.